Now fully revised and in its fifth edition, the Oxford Handbook of Oncology has been the essential go-to guide for students, junior doctors, and medical professionals embarking on a career in oncology for over two decades. The handbook includes an introduction to the scientific basis and diagnosis of cancers, as well as drugs, biomarkers, and the presentation and psychosocial aspects of oncology. Concise, practical, and comprehensive, there is no better companion for both common conditions and challenging emergencies.
The field of oncology has surged forward since the last edition was published and the Oxford Handbook of Oncology has been fully revised and updated to reflect these recent advances so you can be sure that the vital information you need is in your hands. This handbook incorporates changes such as the understanding of the science of cancer, novel therapies in breast, lung, renal, and melanoma, molecular sub-classification of common solid cancers, personalized therapy approaches, new agents in hard to treat cancers, the benefits of new technologies in radiotherapy, and the increasing role of immunotherapy and targeted anti-cancer therapies.
Written by experts in the field to ensure that it is grounded in real life clinical practice, this handbook provides a concise guide to all aspects of oncology for all students, nurses, and junior faculty responsible for the care of cancer patients, while also providing further reading and highlighting areas of controversy for those who need a more detailed understanding.
Miranda Payne, Consultant Medical Oncologist, Oxford University Hospitals NHS Foundation Trust, UK, Gareth Morris-Stiff, Global Chief Medical Officer, Equilibrium Labs, Robert Owens, Consultant Clinical Oncologist, Churchill Hospital, Oxford, UK, Victoria Woodcock, Consultant in Medical Oncology, Oxford University Hospitals NHS Foundation Trust, UK, Rebecca Shakir, Consultant Clinical Oncologist, Churchill Hospital, Oxford, UK, Semini Greening, Medical Oncology Specialty Registrar, Churchill Hospital, Oxford, UK
Miranda Payne is a previous CRUK Clinical Fellow and a current Consultant in Medical Oncology at the Oxford University Hospitals NHS Foundation Trust. Recruitment to international, academic, industry-sponsored and observational clinical trials is a routine aspect of Miranda's clinical practice, reflected in her publication record. She has a particular interest in the consequences of immunotherapy and in the systemic treatment of melanoma. She has been an editor of the Oxford Handbook of Oncology for over 20 years.
Robert Owens is a consultant clinical oncologist in Oxford where he also completed his oncology training. He specialises in treating GI cancers and has a specific interest in focussed targeted radiotherapy (SABR) especially in the upper GI setting.
Gareth Morris Stiff is an accomplished surgical oncologist with 32 years of postgraduate experience with specific expertise in hepato-pancreato-biliary (HPB) cancers, and a Pharma key opinion leader in exocrine pancreatic insufficiency. Extensive research portfolio and widely published in peer-reviewed journals. Numerous leadership roles directing teams and committees within the clinical and research arenas up to a national level. Departed clinical practice to develop anti-cancer therapies with a portfolio including antibodies, small molecules, Ayurvedic-western hybrids, and phytomedicines. Currently global chief medical officer for Equilibrium Labs developing phytomedicines to aid metabolism dysfunction-associated fatty liver disease and cancer chemotherapy-related adverse events.
Victoria Woodcock is a consultant in medical oncology specialising in the treatment of colorectal cancer. She completed her oncology training in Oxford and undertook a DPhil in Oncology at the University of Oxford studying immune responses to checkpoint inhibitor treatment in melanoma. Her academic interests include understanding and augmenting immune responses against cancer through conducting clinical trials of novel immunotherapy treatments and translational research.
Dr Rebecca Shakir is a clinical oncology consultant at the Churchill Hospital in Oxford and post-doctoral academic visitor at Oxford Population Health. Alongside treating people with head and neck and skin cancer, she specialises in the management of people with the long-term side-effects of cancer treatment. Her research focuses on determining the benefits and risks of radiotherapy and shared decision making. In addition to her clinical work, Rebecca is the Sherrington Lecturer at Magdalen College Oxford and a member of the Specialty Training and Professional Standards Boards at the Royal College of Radiologists.
